KESTINE

This brand name is authorized in Estonia, Finland, Italy, Lithuania, Netherlands, Singapore, Turkey, South Africa

Active ingredients

The drug KESTINE contains one active pharmaceutical ingredient (API):

1 Ebastine UNII TQD7Q784P1 - EBASTINE

Ebastine has been shown to produce a rapid and long-lasting inhibition of histamine-induced effect and to have a strong affinity towards H1-receptors. Read about Ebastine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
KESTINE Coated tablet	Web Search	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R06AX22	Ebastine	R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AX Other antihistamines for systemic use
Discover more medicines within R06AX22

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1009976, 1077937, 1077948, 1081617, 1120330, 1120341, 1120352, 1137046
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 015084, 015095, 015515, 023058, 023420, 065140
Country: IT	Agenzia del Farmaco	Identifier(s): 034930014, 034930141
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1003913, 1011680, 1012601, 1086459, 1087824
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 46922
Country: SG	Health Sciences Authority	Identifier(s): 09435P, 15644P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699586092121, 8699586092237
Country: ZA	Health Products Regulatory Authority	Identifier(s): 29/5.7.1/0344